Heartflow, Inc. (HTFL) – What Are Investment Firms Saying About This Stock?

Heartflow, Inc. (NASDAQ:HTFL) has been given an average rating of “Moderate Buy” by the twelve research firms that are presently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell recommendation, two have given a hold recommendation, eight have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $48.62.

A number of brokerages have recently issued reports on HTFL. Weiss Ratings reissued a “sell (d-)” rating on shares of Heartflow in a report on Wednesday. Canaccord Genuity Group boosted their price objective on shares of Heartflow from $45.00 to $56.00 and gave the company a “buy” rating in a research note on Tuesday, September 22nd. Morgan Stanley increased their target price on shares of Heartflow from $35.00 to $40.00 and gave the stock an “equal weight” rating in a research note on Friday, August 14th. Benchmark reissued a “buy” rating on shares of Heartflow in a report on Friday, August 14th. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $64.00 price target (up from $45.00) on shares of Heartflow in a report on Tuesday, October 20th.

Heartflow Stock Performance

NASDAQ:HTFL opened at $52.40 on Friday. Heartflow has a 52-week low of $20.13 and a 52-week high of $60.56. The firm has a market cap of $4.56 billion, a price-to-earnings ratio of -28.63 and a beta of 2.50. The business’s fifty day moving average is $51.28 and its 200 day moving average is $34.64.

Heartflow (NASDAQ:HTFL) last issued its earnings results on Thursday, August 13th. The company reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.22) by $0.15. The business had revenue of $64.08 million during the quarter. Heartflow had a negative return on equity of 23.52% and a negative net margin of 55.82%. The business’s quarterly revenue was up 47.7% on a year-over-year basis. Equities analysts predict that Heartflow will post -0.75 EPS for the current fiscal year.

Insider Buying and Selling

In other news, insider Campbell Rogers sold 23,933 shares of Heartflow stock in a transaction dated Thursday, October 22nd. The stock was sold at an average price of $55.01, for a total transaction of $1,316,554.33. Following the completion of the sale, the insider owned 73,453 shares in the company, valued at approximately $4,040,649.53. This trade represents a 24.58% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO John Farquhar sold 38,900 shares of Heartflow stock in a transaction dated Monday, October 12th. The shares were sold at an average price of $49.57, for a total value of $1,928,273.00. Following the sale, the chief executive officer owned 283,014 shares of the company’s stock, valued at approximately $14,029,003.98. This trade represents a 12.08% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 328,038 shares of company stock worth $15,490,354 over the last ninety days. 7.70% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Heartflow

Several hedge funds have recently bought and sold shares of the stock. Allworth Financial LP lifted its holdings in shares of Heartflow by 116.4% in the 3rd quarter. Allworth Financial LP now owns 1,145 shares of the company’s stock worth $57,000 after acquiring an additional 616 shares during the last quarter. Pier 88 Investment Partners LLC bought a new stake in Heartflow in the third quarter worth $174,000. M&G PLC purchased a new stake in Heartflow during the third quarter valued at about $15,978,000. Pictet Asset Management Holding SA purchased a new position in shares of Heartflow in the third quarter worth about $551,000. Finally, Inscription Capital LLC purchased a new position in shares of Heartflow in the third quarter worth about $209,000.

Heartflow Company Profile

Heartflow, Inc is a medical technology company that develops artificial intelligence-based tools to help physicians diagnose and manage coronary artery disease. Its platform uses data from coronary computed tomography angiography (CCTA) scans to create personalized, three-dimensional models of a patient’s coronary arteries and provide noninvasive assessments of blood flow and disease.

The company’s products include Heartflow Analysis, which provides fractional flow reserve computed tomography (FFR-CT) evaluations to help identify potentially significant blockages, as well as tools for assessing coronary plaque and planning treatment.